Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Change in Accured Expenses for 6 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 60.28% year-over-year to $4.7 million, compared with a TTM value of $4.0 million through Dec 2025, up 585.92%, and an annual FY2025 reading of $4.0 million, up 585.92% over the prior year.
  • Change in Accured Expenses was $4.7 million for Q4 2025 at Cytek Biosciences, up from -$1.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.9 million in Q4 2021 and bottomed at -$4.8 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $1.1 million, with a median of $462500.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 2368.91% in 2024, while the deepest fall reached 360.86% in 2024.
  • Year by year, Change in Accured Expenses stood at $8.9 million in 2021, then crashed by 47.72% to $4.6 million in 2022, then crashed by 97.44% to $119000.0 in 2023, then soared by 2368.91% to $2.9 million in 2024, then skyrocketed by 60.28% to $4.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CTKB at $4.7 million in Q4 2025, -$1.4 million in Q3 2025, and $2.8 million in Q2 2025.